10
Dec
2024

Sichuan Huiyu Pharmaceutical Co.,Ltd

Exhibitor at CPHI Middle East 2024 stand 1.G54
About Us

Huiyu pharm, founded in 2010, is a comprehensive pharmaceutical enterprise driven by research and development, mainly engaged in the research and development, production, and sales of anti-tumor injection.Also,it's dedicated to R&D and manufacturing of API products, with facilities approved by EU EDQM and China NMPA.Huiyu's products range from oncology,anti-infective to IDA, etc.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Middle East 2024
  • 10 Dec 2024 - 12 Dec 2024
  • Riyadh Front Exhibition & Convention Center Riyadh, Saudi Arabia
  • Visit us at stand 1.G54

Products Featured at CPHI Middle East 2024

  • Azacitidine Seacross 25mg/ml Powder for suspension for injection

    Product Azacitidine Seacross 25mg/ml Powder for suspension for injection

    Therapeutic indications:Azacitidine Seacross is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

    •intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System ...
  • Zoledronic Acid Seacross 5mg/100ml solution for infusion

    Product Zoledronic Acid Seacross 5mg/100ml solution for infusion

    Therapeutic indications:  
    Treatment of osteoporosis：•in post-menopausal women•in adult men at increased risk of fracture, including those with a recent low-trauma hip fracture.Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy： •in post-menopausal wo...
  • Docetaxel 20 mg/ml Concentrate for solution for infusion

    Product Docetaxel 20 mg/ml Concentrate for solution for infusion

    Therapeutic indications:Breast cancer, sarcoma, small-cell carcinoma of the lung, Hodgkin disease or non-Hodgkin lymphoma, acute leukaemia, cancer of the thyroid, bladder, ovaries, Paediatric tumours, such as neuroblastoma. Doxorubicin is frequently used in combination chemotherapy regimens with other...
  • API: Carfilzomib/Bortezomib/Thiotepa/Ferric Carboxymaltose/Goserelin acetate/Ixazomib citrate

    Product API: Carfilzomib/Bortezomib/Thiotepa/Ferric Carboxymaltose/Goserelin acetate/Ixazomib citrate

    ——1. Carfilzomib: commercial API, DMF available, W.C. to be available in April 2024 2024)——Bortezomib: commercial API, DMF available, W.C. to be available in April 2024
    ——2. Thiotepa: 
    Commercial API, DMF available, W.C. to be available in April 2024
    ——3. Ferric carboxymaltose: ...
  • Paclitaxel 6 mg/ml concentrate for solution for infusion

    Product Paclitaxel 6 mg/ml concentrate for solution for infusion

    Paclitaxel Injection is used to treat:

    Ovarian cancer:

    • as first therapy (after initial surgery in combination with the platinum-containing medicine cisplatin).

    • after standard platinum-containing medicines have been tried but did not work.
    ...
  • Pemetrexed Seacross 100 mg / 500 mg powder for concentrate for solution for infusion

    Product Pemetrexed Seacross 100 mg / 500 mg powder for concentrate for solution for infusion

    Therapeutic indications: 

    • Malignant pleural mesothelioma

    in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.


    • Non-small cell lung cancer

    in c...
  • Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion

    Product Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion

    Irinotecan is indicated for the treatment of patients with advanced colorectal cancer:
    in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, as a single agent in patients who have failed an established 5-fluorouracil containing treatment regim...
  • Oxaliplatin 5mg/ml concentrate for solution for infusion

    Product Oxaliplatin 5mg/ml concentrate for solution for infusion

    Therapeutic indications: Oxaliplatin in combination with 5-fluorouracil (5-FU) and folinic acid (FA) is indicated for:Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of primary tumour. Treatment of metastatic colorectal cancer.
  • Zoledronic acid 4 mg/5 ml concentrate for solution for infusion

    Product Zoledronic acid 4 mg/5 ml concentrate for solution for infusion

    Therapeutic indications:
    -To prevent bone complications, e.g. fractures, in adult patients with bone metastases (spread of cancer from primary site to the bone).


    -To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour. Tumours...
  • Docetaxel 20 mg/ml Concentrate for Solution for Infusion

    Product Docetaxel 20 mg/ml Concentrate for Solution for Infusion

    Docetaxel is used for the treatment of breast cancer, special forms of lung cancer (non-small cell lung cancer), prostate cancer, gastric cancer or head and neck cancer.

    • For the treatment of advanced breast cancer, Docetaxel could be administered either alone or in combination with doxorub...